CN109071585B - 预防和治疗半乳糖凝集素相关疾病的硒代半乳糖苷化合物及其用途 - Google Patents

预防和治疗半乳糖凝集素相关疾病的硒代半乳糖苷化合物及其用途 Download PDF

Info

Publication number
CN109071585B
CN109071585B CN201780027703.5A CN201780027703A CN109071585B CN 109071585 B CN109071585 B CN 109071585B CN 201780027703 A CN201780027703 A CN 201780027703A CN 109071585 B CN109071585 B CN 109071585B
Authority
CN
China
Prior art keywords
galectin
substituted
group
compound
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780027703.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN109071585A (zh
Inventor
S·谢克特尔
E·佐默
P·G·特拉伯
R·尼尔
J·M·约翰逊
R·乔治
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galectin Sciences LLC
Original Assignee
Galectin Sciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galectin Sciences LLC filed Critical Galectin Sciences LLC
Publication of CN109071585A publication Critical patent/CN109071585A/zh
Application granted granted Critical
Publication of CN109071585B publication Critical patent/CN109071585B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201780027703.5A 2016-03-04 2017-03-03 预防和治疗半乳糖凝集素相关疾病的硒代半乳糖苷化合物及其用途 Active CN109071585B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662303872P 2016-03-04 2016-03-04
US62/303,872 2016-03-04
PCT/US2017/020658 WO2017152048A1 (en) 2016-03-04 2017-03-03 Selenogalactoside compounds for the prevention and treatment of diseases associated with galectin and the use thereof

Publications (2)

Publication Number Publication Date
CN109071585A CN109071585A (zh) 2018-12-21
CN109071585B true CN109071585B (zh) 2022-08-16

Family

ID=59744474

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780027703.5A Active CN109071585B (zh) 2016-03-04 2017-03-03 预防和治疗半乳糖凝集素相关疾病的硒代半乳糖苷化合物及其用途

Country Status (11)

Country Link
US (2) US20190367552A1 (https=)
EP (1) EP3423461A4 (https=)
JP (1) JP7086008B2 (https=)
KR (1) KR102346913B1 (https=)
CN (1) CN109071585B (https=)
AU (1) AU2017228365B2 (https=)
CA (1) CA3016343C (https=)
IL (2) IL261431B (https=)
MX (1) MX394409B (https=)
WO (1) WO2017152048A1 (https=)
ZA (1) ZA201805900B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3062648A1 (en) * 2017-05-12 2018-11-15 Galectin Sciences, Llc Compounds for the prevention and treatment of diseases and the use thereof
AU2018361991A1 (en) * 2017-10-31 2020-05-14 Galectin Sciences, Llc Selenogalactoside compounds for the treatment of systemic insulin resistance disorders and the use thereof
AU2020214796A1 (en) * 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
CN114206893A (zh) * 2019-08-09 2022-03-18 爱杜西亚药品有限公司 (杂)芳基-甲基-硫代-β-D-吡喃半乳糖苷衍生物
CN113476442A (zh) * 2021-07-28 2021-10-08 上海交通大学医学院附属第九人民医院 化合物gb-0139在治疗心肌梗死后心肌过度纤维化的药物中的应用
JP2025511354A (ja) 2022-04-06 2025-04-15 シャペロン インク． タウロデオキシコール酸又はその薬学的に許容される塩を有効成分として含有する肺線維症の予防又は治療用組成物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102439021A (zh) * 2009-04-28 2012-05-02 南方佛斯卡专利公司 半乳凝素的新型半乳糖苷抑制剂
CN104066743A (zh) * 2012-01-25 2014-09-24 格莱克特生物技术公司 半乳糖凝集素的新型半乳糖苷抑制剂
CN104755088A (zh) * 2012-10-31 2015-07-01 格莱克特生物技术公司 半乳凝集素-3的半乳糖苷抑制剂及其用于治疗肺纤维化的应用
WO2015138438A1 (en) * 2014-03-10 2015-09-17 La Jolla Pharmaceutical Company Compositions and methods for treating kidney disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401301D0 (sv) * 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
CA2668693A1 (en) * 2006-11-15 2008-05-22 David E. Anderson Therapeutic uses of tim-3 modulators
CA2794066C (en) * 2012-10-31 2017-02-28 Neil Henderson Galactoside inhibitor of galectins
ES2869884T3 (es) * 2011-09-16 2021-10-26 Galectin Therapeutics Inc Composiciones de galacto-ramnogalacturonato para el tratamiento de la esteatohepatitis no alcohólica y la enfermedad de hígado graso no alcohólico
AU2012363033B2 (en) * 2011-12-28 2016-06-02 Galectin Therapeutics, Inc. Composition of novel carbohydrate drug for treatment of human diseases
WO2014078655A1 (en) * 2012-11-15 2014-05-22 Tufts University Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor
EP3129032A1 (en) * 2014-04-08 2017-02-15 Galecto Biotech AB Galactoside inhibitors for the treatment of alpha-synucleinopthies

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102439021A (zh) * 2009-04-28 2012-05-02 南方佛斯卡专利公司 半乳凝素的新型半乳糖苷抑制剂
CN104066743A (zh) * 2012-01-25 2014-09-24 格莱克特生物技术公司 半乳糖凝集素的新型半乳糖苷抑制剂
CN104755088A (zh) * 2012-10-31 2015-07-01 格莱克特生物技术公司 半乳凝集素-3的半乳糖苷抑制剂及其用于治疗肺纤维化的应用
WO2015138438A1 (en) * 2014-03-10 2015-09-17 La Jolla Pharmaceutical Company Compositions and methods for treating kidney disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Convenient syntheses of 1,2-trans selenoglycosides using isoselenuronium salts as glycosylselenenyl transfer reagents;Ambati Ashok Kumar et al.;《Carbohydrate Research》;20120725;第360卷;第8-18页 *
Sabine Andre et al..Thio- and selenoglycosides as ligands for biomedically relevant lectins: Valency–activity correlations for benzene-based dithiogalactoside clusters and first assessment for (di)selenodigalactosides.《Bioorganic & Medicinal Chemistry Letters》.2014,第25卷 *
Thio- and selenoglycosides as ligands for biomedically relevant lectins: Valency–activity correlations for benzene-based dithiogalactoside clusters and first assessment for (di)selenodigalactosides;Sabine Andre et al.;《Bioorganic & Medicinal Chemistry Letters》;20141220;第25卷;第931-935页 *

Also Published As

Publication number Publication date
MX394409B (es) 2025-03-24
IL281585B (en) 2022-04-01
CN109071585A (zh) 2018-12-21
IL261431A (en) 2018-10-31
US20230127345A1 (en) 2023-04-27
IL261431B (en) 2021-04-29
KR20180128419A (ko) 2018-12-03
CA3016343C (en) 2024-03-26
US20190367552A1 (en) 2019-12-05
ZA201805900B (en) 2019-07-31
JP7086008B2 (ja) 2022-06-17
CA3016343A1 (en) 2017-09-08
JP2019507194A (ja) 2019-03-14
AU2017228365B2 (en) 2021-05-27
MX2018010683A (es) 2019-05-27
AU2017228365A1 (en) 2018-09-27
IL281585A (en) 2021-05-31
BR112018067693A2 (pt) 2019-01-08
KR102346913B1 (ko) 2022-01-04
EP3423461A1 (en) 2019-01-09
EP3423461A4 (en) 2020-03-25
WO2017152048A1 (en) 2017-09-08

Similar Documents

Publication Publication Date Title
CN109071585B (zh) 预防和治疗半乳糖凝集素相关疾病的硒代半乳糖苷化合物及其用途
US20230132265A1 (en) Compounds for the prevention and treatment of diseases and the use thereof
WO2019089080A9 (en) Selenogalactoside compounds for the treatment of systemic insulin resistance disorders and the use thereof
CN111032670A (zh) 用于治疗系统性胰岛素抗性病症的化合物及其用途
JP7498108B2 (ja) 医学的障害の予防および治療のための化合物およびその使用
BR112018067693B1 (pt) Selenogalactosídeos, seus usos, e composição

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant